This trispecific T cell engager incorporates CD28 co-stimulation and has shown potent antitumor activity in preclinical models including small cell lung cancer. These cancers are notoriously hard ...

1-9 These therapies incorporate either a 4-1BB (CD137) or a CD28 intracellular costimulatory domain to enhance T-cell activation and persistence. Despite these advancements, more than 50% of ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response ...

After spending years tracing the origin and migration pattern of an unusual type of immune cell in mice, researchers headed by a team at The Ohio State University College of Medicine have shown ...

French cell therapy company Celyad is also working in the area, its lead candidate CYAD-01 is an autologous CAR-T NKG2D therapy for use in haematological and solid cancers.

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Zymeworks Inc. (ZYME) reported a significant increase in revenue for Q1 2025, rising to $27.1 million from $10 million in Q1 2024, primarily due to milestone payments from partners like GSK and ...

What is Known About the Estrogen Deficiency of Menopause & Specific Autoimmune Diseases It is known that many natural, pathological and therapeutic conditions can change serum estrogen levels ...

Tumor immune evasion can be accomplished through the induction of T cell exhaustion via the activation of various immune checkpoint molecules. The most prominent examples of immune checkpoints are ...

“Some of these are helpful, like the memory T cell compartment and and the [natural killer] cell compartments, they prevent relapses, but a lot of these naive T cells are responsible for causing graft ...